• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Pseudomonas Aeruginosa Infections - Pipeline Review, H2 2012 Product Image

Pseudomonas Aeruginosa Infections - Pipeline Review, H2 2012

  • Published: November 2012
  • 100 pages
  • Global Markets Direct

Pseudomonas Aeruginosa Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Pseudomonas Aeruginosa Infections - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Pseudomonas Aeruginosa Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pseudomonas Aeruginosa Infections. Pseudomonas Aeruginosa Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Pseudomonas Aeruginosa Infections.
- A review READ MORE >

2
List of Tables 5
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Pseudomonas Aeruginosa Infections Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Pseudomonas Aeruginosa Infections 9
Pseudomonas Aeruginosa Infections Therapeutics under Development by Companies 11
Pseudomonas Aeruginosa Infections Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Pseudomonas Aeruginosa Infections Therapeutics – Products under Development by Companies 19
Pseudomonas Aeruginosa Infections Therapeutics – Products under Investigation by Universities/Institutes 20
Companies Involved in Pseudomonas Aeruginosa Infections Therapeutics Development 21
Sanofi-Aventis 21
Targeted Genetics Corporation 22
Merck & Co., Inc. 23
Rib-X Pharmaceuticals, Inc. 24
Bayer AG 25
PARI Pharma GmbH 26
Insmed Incorporated 27
Achaogen Inc. 28
Mondobiotech Holding AG 29
Kenta Biotech Ltd. 30
Microbiotix, Inc. 31
Ancora Pharmaceuticals Inc. 32
Tetraphase Pharmaceuticals Inc. 33
Phico Therapeutics Ltd. 34
SelectX Pharmaceuticals, Inc. 35
Trana Discovery, Inc. 36
Cantab Biopharmaceuticals Limited 37
Pseudomonas Aeruginosa Infections – Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
ciprofloxacin - Drug Profile 43
amikacin - Drug Profile 45
ACHN-975 - Drug Profile 47
panobacumab - Drug Profile 48
RX-04 - Drug Profile 50
KBPA-104 - Drug Profile 51
KBPA-103 - Drug Profile 52
KBPA-102 - Drug Profile 53
tobramycin - Drug Profile 54
tobramycin - Drug Profile 56
DasKloster-027401 - Drug Profile 57
SASPject PT3.1 - Drug Profile 58
SASPject PT3.X - Drug Profile 59
TP-433 - Drug Profile 60
RX-P792 - Drug Profile 61
RX-P793 - Drug Profile 62
RX-P808 - Drug Profile 63
RX-P770 - Drug Profile 65
Gram-Negative Programme - Drug Profile 67
PopB-Based Vaccine - Drug Profile 68
ACHN-978 - Drug Profile 69
Pseudovac Vaccine - Drug Profile 70
Snare Antibacterial For Gram Negative Infections - Drug Profile 71
Carbavance - Drug Profile 72
Immunoglobulin Y - Drug Profile 73
Pseudomonas aeruginosa Vaccine - Drug Profile 74
Vaccine for Pseudomonas - Drug Profile 75
Antibiotics For Hospital-Acquired Gram-Negative Bacterial Infections - Drug Profile 76
SXP-2554 - Drug Profile 77
BioPhage-PR - Drug Profile 78
Type III secretion system (T3SS) Inhibitors - Drug Profile 79
Pseudomonas Aeruginosa Infections Therapeutics – Drug Profile Updates 80
Pseudomonas Aeruginosa Infections Therapeutics - Dormant Products 88
Pseudomonas Aeruginosa Infections – Product Development Milestones 89
Featured News & Press Releases 89
Appendix 97
Methodology 97
Coverage 97
Secondary Research 97
Primary Research 97
Expert Panel Validation 97
Contact Us 98
Disclaimer 98

List of Tables
Number of Products Under Development for Pseudomonas Aeruginosa Infections, H2 2012 11
Products under Development for Pseudomonas Aeruginosa Infections – Comparative Analysis, H2 2012 12
Number of Products under Development by Companies, H2 2012 14
Number of Products under Development by Companies, H2 2012 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2012 16
Comparative Analysis by Late Stage Development, H2 2012 17
Comparative Analysis by Mid Clinical Stage Development, H2 2012 18
Comparative Analysis by Early Clinical Stage Development, H2 2012 19
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 20
Products under Development by Companies, H2 2012 21
Products under Investigation by Universities/Institutes, H2 2012 22
Sanofi-Aventis, H2 2012 23
Targeted Genetics Corporation, H2 2012 24
Merck & Co., Inc., H2 2012 25
Rib-X Pharmaceuticals, Inc., H2 2012 26
Bayer AG, H2 2012 27
PARI Pharma GmbH, H2 2012 28
Insmed Incorporated, H2 2012 29
Achaogen Inc., H2 2012 30
Mondobiotech Holding AG, H2 2012 31
Kenta Biotech Ltd., H2 2012 32
Microbiotix, Inc., H2 2012 33
Ancora Pharmaceuticals Inc., H2 2012 34
Tetraphase Pharmaceuticals Inc., H2 2012 35
Phico Therapeutics Ltd., H2 2012 36
SelectX Pharmaceuticals, Inc., H2 2012 37
Trana Discovery, Inc., H2 2012 38
Cantab Biopharmaceuticals Limited, H2 2012 39
Assessment by Monotherapy Products, H2 2012 40
Assessment by Stage and Route of Administration, H2 2012 42
Assessment by Stage and Molecule Type, H2 2012 44
Pseudomonas Aeruginosa Infections Therapeutics – Drug Profile Updates 82
Pseudomonas Aeruginosa Infections Therapeutics – Dormant Products 90

List of Figures
Number of Products under Development for Pseudomonas Aeruginosa Infections, H2 2012 11
Products under Development for Pseudomonas Aeruginosa Infections – Comparative Analysis, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 16
Late Stage Products, H2 2012 17
Mid Clinical Stage Products, H2 2012 18
Early Clinical Stage Products, H2 2012 19
Discovery and Pre-Clinical Stage Products, H2 2012 20
Assessment by Monotherapy Products, H2 2012 40
Assessment by Route of Administration, H2 2012 41
Assessment by Stage and Route of Administration, H2 2012 42
Assessment by Molecule Type, H2 2012 43
Assessment by Stage and Molecule Type, H2 2012 44

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos